-
In a large, well-designed observational study of patients with COPD, treatment with β-blockers during a mean follow-up period of 7.2 years was found not only to reduce the risk of exacerbations, but also to improve survival.
-
-
Fibrates: Generally safe, but do they improve outcomes? According to this meta-analysis, the answer to the question above very much depends upon which outcome you believe is important.
-
The first receptor activator of nuclear factor kappa-B ligand (RANKL) inhibitor has been approved for the treatment of osteoporosis.
-
There is no difference in rates of treatment failure, death, or readmission for COPD between patients treated with oral or intravenous steroids for exacerbation of COPD, but the IV route may be associated with increased cost and length of stay.
-
A systematic review of 9 studies showed that the COX-2 inhibitor celecoxib and ibuprofen cause less upper GI bleeding than other NSAIDs. Diclofenac, meloxicam, ketoprofen, indomethacin, and naproxen have intermediate risk. Piroxicam and ketorolac have the highest risk. In general, drugs that have a long half-life or slow-release formulation have the greatest risk of GI bleeding.
-
Aggressive approach to CVD reduces MI, folic acid and vitamin B12 for CAD, corticosteroids for acute exacerbations of COPD, prescription drug abuse among young adults, and ARBs and cancer risk.
-
The ECG shown above was obtained from a 77-year-old woman with chest discomfort and a permanent pacemaker. Do you see any abnormality on this paced tracing?
-
The addition of CACS to a prediction model based upon the traditional risk factors significantly improved the classification of risk and helped to place more individuals in their appropriate risk categories.
-